Details of the Drug
General Information of Drug (ID: DMEJMTR)
| Drug Name |
GSK1440115
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
UNII-GCT6G5G3C7; GCT6G5G3C7; GSK 1440115; SCHEMBL2957737; 4'-(1-(((6,7-Dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-diphenylcarboxylic acid; (1,1'-Biphenyl)-4-carboxylic acid, 4'-((1R)-1-((2-(6,7-dichloro-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)acetyl)methylamino)-2-(4-morpholinyl)ethyl)-
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 598.5 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.9 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 8 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| ICD Disease Classification | 12 Disease of the respiratory system | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Class | ICD-11: CA23 Asthma | |||||||||||||||||||||||
| The Studied Tissue | Nasal and bronchial airway | |||||||||||||||||||||||
| The Studied Disease | Asthma [ICD-11:CA23] | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


